Johnson & Johnson Updates Guidance After Firefly, Sail Deals
I'm LongbridgeAI, I can summarize articles.Johnson & Johnson updated its financial guidance following the $1 billion acquisition of Firefly Bio and strategic deals with Sail Biomedicines. These transactions are expected to reduce 2026 adjusted EPS by approximately $0.64 and 2027 EPS by $1.36, reflecting near-term earnings pressure to advance oncology innovation. Despite the guidance cut, analysts maintain a 'Buy' rating with a $300 price target, citing strong financial quality and positive long-term outlook.
An announcement from Johnson & Johnson ( (JNJ) ) is now available.
On July 29, 2026, Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, Inc., gaining the Firelink degrader antibody conjugate platform to enhance its oncology portfolio and capabilities in targeting KRAS-driven and other difficult solid tumors. The deal, accounted for as an asset acquisition, will trigger an approximately $1 billion in‑process R&D charge in the third quarter of 2026 and is expected to dilute adjusted earnings by $0.46 per share in 2026 and $0.08 in 2027.
Separately, on July 29, 2026, the company disclosed strategic agreements and a collaboration with Sail Biomedicines, prompting a cut to its full‑year 2026 guidance as the Firefly and Sail transactions together are expected to reduce 2026 adjusted operational EPS and adjusted EPS by about $0.64. The combined impact is also projected to lower 2027 adjusted operational EPS and adjusted EPS by roughly $1.36, underscoring Johnson & Johnson’s willingness to absorb near‑term earnings pressure to advance its position in next‑generation oncology innovation and RNA‑based therapeutics.
The most recent analyst rating on (JNJ) stock is a Buy
with a $300.00 price target.
To see the full list of analyst forecasts on Johnson & Johnson stock,
see the JNJ Stock Forecast page.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
JNJ scores well primarily on strong underlying financial quality (high margins, low leverage, solid free cash flow) and a positive earnings update with raised FY26 guidance and improved margin outlook. The uptrend in price versus key moving averages adds support. The biggest offset is valuation (P/E ~30.8 with a ~2% yield), while the talc settlement proposal modestly reduces legal overhang but still carries execution uncertainty.
To see Spark’s full report on JNJ stock,
click here.
More about Johnson & Johnson
Johnson & Johnson is a global healthcare company operating across Innovative Medicine and MedTech, developing and commercializing therapies and devices that prevent, treat and cure complex diseases. With decades of leadership in oncology, it focuses on next-generation antibody engineering and targeted cancer treatments, particularly for hard-to-treat solid tumors where significant unmet medical need remains.
Average Trading Volume: 8,295,514
Technical Sentiment Signal: Strong Buy
Current Market Cap: $640.9B